Business Description
Tissue Regenix Group PLC
SIC : 3841
ISIN : GB00BNTXR104
Total Employee Number:
19Description
Tissue Regenix Group PLC is a UK-based medical technology company that develops, processes, and commercializes regenerative tissue products for surgical and clinical applications. It uses two proprietary platform technologies, dCELL and BioRinse, to produce acellular biological scaffolds and tissue-based implants. Its product portfolio spans musculoskeletal, dermis, soft tissue, and birth tissue applications, including the OrthoPure range of soft tissue products. The company's principal processing and manufacturing operations are located in San Antonio, Texas, where most dCELL and BioRinse products are made, alongside a facility in Leeds, United Kingdom, focused on porcine soft tissue processing. Tissue Regenix sells primarily to hospitals, surgeons, and healthcare providers, generating most of its revenue in the United States, with additional sales across other international markets. Revenue comes from the sale of its regenerative medical devices and tissue products.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.34 | |||||
Equity-to-Asset | 0.45 | |||||
Debt-to-Equity | 0.93 | |||||
Debt-to-EBITDA | -2.06 | |||||
Piotroski F-Score | 1/9 | |||||
Altman Z-Score | -4.14 | |||||
Beneish M-Score | -1.71 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 1.3 | |||||
3-Year EBITDA Growth Rate | -100 | |||||
3-Year FCF Growth Rate | -16.8 | |||||
3-Year Book Growth Rate | -18 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 17.59 | |||||
9-Day RSI | 11.63 | |||||
14-Day RSI | 7.61 | |||||
3-1 Month Momentum % | -28.22 | |||||
6-1 Month Momentum % | -74.56 | |||||
12-1 Month Momentum % | -87.61 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.8 | |||||
Quick Ratio | 1.69 | |||||
Cash Ratio | 0.92 | |||||
Days Inventory | 188.15 | |||||
Days Sales Outstanding | 49.29 | |||||
Days Payable | 64.78 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.4 | |||||
Shareholder Yield % | -50.73 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 9.39 | |||||
Operating Margin % | -31.52 | |||||
Net Margin % | -38.95 | |||||
EBITDA Margin % | -30.31 | |||||
FCF Margin % | -17.21 | |||||
OCF Margin % | -5.34 | |||||
ROE % | -41.31 | |||||
ROA % | -23.71 | |||||
ROIC % | -22.59 | |||||
3-Year ROIIC % | 64.79 | |||||
ROC (Joel Greenblatt) % | -50.42 | |||||
ROCE % | -25.9 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 61 | |||||
PS Ratio | 0.2 | |||||
PB Ratio | 0.3 | |||||
Price-to-Tangible-Book | 1.45 | |||||
EV-to-EBIT | -1.48 | |||||
EV-to-Forward-EBIT | 9.88 | |||||
EV-to-EBITDA | -1.73 | |||||
EV-to-Forward-EBITDA | 7.5 | |||||
EV-to-Revenue | 0.53 | |||||
EV-to-Forward-Revenue | 0.69 | |||||
EV-to-FCF | -3.5 | |||||
Price-to-GF-Value | 0.08 | |||||
Earnings Yield (Greenblatt) % | -67.57 | |||||
FCF Yield % | -73.77 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Tissue Regenix Group PLC Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil £) | 20.125 | ||
| EPS (TTM) (£) | -0.015 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | -1.17 | ||
| 3-Year Sortino Ratio | -1.22 | ||
| Volatility % | 70.75 | ||
| 14-Day RSI | 7.61 | ||
| 14-Day ATR (£) | 0.016295 | ||
| 20-Day SMA (£) | 0.110263 | ||
| 12-1 Month Momentum % | -87.61 | ||
| 52-Week Range (£) | 0.0477 - 0.616 | ||
| Shares Outstanding (Mil) | 71.23 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Tissue Regenix Group PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Tissue Regenix Group PLC Stock Events
| Event | Date | Price (£) | ||
|---|---|---|---|---|
| Second quarter earnings conference call for 2026 | 2026-09-30 15:00 | In 9 days | ||
| Second quarter earnings results for 2026 | 2026-09-30 | In 8 days | ||
| General meeting for 2026 | 2026-07-23 12:00 | 0.07 (+0.00%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-07-01 13:00 | 0.07 (+0.00%) | ||
| Annual report for 2025 | 2026-06-26 | 0.07 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-06-25 | 0.07 (+0.00%) | ||
| Second quarter earnings conference call for 2025 | 2025-09-30 15:00 | 0.21 (-4.55%) | ||
| Second quarter earnings results for 2025 | 2025-09-30 | 0.21 (-4.55%) | ||
| General meeting for 2025 | 2025-07-23 12:00 | 0.37 (+12.31%) | ||
| Fourth quarter earnings conference call for 2024 | 2025-07-01 13:00 | 0.30 (+0.00%) |
Show
Entries
Tissue Regenix Group PLC Frequently Asked Questions
What is Tissue Regenix Group PLC(LSE:TRX)'s stock price today?
The current price of LSE:TRX is £0.07. The 52 week high of LSE:TRX is £0.62 and 52 week low is £0.05.
When is next earnings date of Tissue Regenix Group PLC(LSE:TRX)?
The next earnings date of Tissue Regenix Group PLC(LSE:TRX) is 2026-09-30 Est..
Does Tissue Regenix Group PLC(LSE:TRX) pay dividends? If so, how much?
Tissue Regenix Group PLC(LSE:TRX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers